AseBio

Lung cancer: from early detection of recurrence to new therapies, biotechnology takes on one of oncology’s greatest challenges

On the occasion of International Lung Cancer Awareness Day, we highlight the advances made by Flomics Biotech and Oryzon Genomics in developing tools to detect recurrence and new therapeutic strategies that contribute to more precise and personalised medicine.

Científica en el laboratorio
Healthcare
In vitro diagnostics
Personalized medicine

Lung cancer remains one of the world's major public health challenges, due to both its high incidence and mortality. The fact that the disease is often detected at advanced stages, its biological complexity and the need to improve treatment options highlight the importance of continuing to promote prevention, early diagnosis and scientific research.

According to the latest estimates from the International Agency for Research on Cancer (IARC), published in July 2026, approximately 2.6 million new cases of lung cancer were diagnosed worldwide in 2024, accounting for 12.8% of all cancer diagnoses. That same year, the disease caused around 1.9 million deaths, representing 19.1% of all cancer deaths, making it the most commonly diagnosed cancer and the leading cause of cancer-related mortality worldwide.

In Spain, according to the report Cancer Figures in Spain 2026, prepared by the Spanish Society of Medical Oncology (SEOM) and the Spanish Network of Cancer Registries (REDECAN), an estimated 34,908 new cases of lung cancer will be diagnosed in 2026, making it one of the most common cancers in the country. 

Furthermore, the latest available mortality data, corresponding to 2024, show that lung cancer remains the leading cause of cancer-related death among men and has overtaken breast cancer as the leading cause of cancer-related death among women.

Against this backdrop, biotechnology is opening up new opportunities to improve lung cancer monitoring and treatment. Research into risk factors, the development of molecular diagnostic tools and new therapeutic strategies are helping to advance towards a more precise and personalised approach to the disease.

On the occasion of International Lung Cancer Awareness Day, observed every 17 November, at the Spanish Bioindustry Association (AseBio), we explore the work of two of our members, Flomics Biotech and Oryzon Genomics, which are developing innovative solutions to tackle this disease through different areas of biotechnology research.

Liquid biopsy and artificial intelligence to anticipate lung cancer recurrence

One of the main challenges in lung cancer management is the early detection of potential recurrence, even in patients diagnosed at early stages and treated with surgery. Currently, follow-up relies primarily on imaging tests, which can identify recurrence once the tumour has grown sufficiently but cannot detect the small numbers of cancer cells that may remain after treatment, known as minimal residual disease.

 

In this context, liquid biopsy is emerging as a promising tool for improving patient monitoring, as it can identify tumour signals through a blood sample. Because it is minimally invasive, the test can be repeated over time. However, detecting these signals at early stages remains a challenge. As Esther Lizano, co-founder and Business Development Director at Flomics Biotech, explains, “the future lies in combining multiple layers of molecular information, rather than relying solely on circulating tumour DNA.”

This is precisely the aim of LUMINA, a European project under the Eurostars programme, coordinated by Flomics Biotech, which is developing a tool to detect minimal residual disease in patients with stage I–III lung adenocarcinoma. The initiative seeks to integrate information from circulating cell-free DNA, including mutations, methylation and fragmentation patterns, and circulating cell-free RNA, which provides insights into which genes are active in the tumour and its surrounding environment, into a single blood test.

To achieve this, Flomics contributes its proprietary cell-free RNA sequencing technology and bioinformatics models, working alongside partners from Sweden and the Netherlands, including Uppsala University. The project has finalised agreements to access patient plasma samples from biobanks, is preparing the collection of new samples and has begun adapting its mutation-detection software for the analysis of cell-free DNA and RNA.

Artificial intelligence plays a fundamental role in this approach, enabling the integration of thousands of molecular signals that would be too weak to yield meaningful conclusions if analysed individually. According to Lizano, this technology makes it possible to turn that information “into a clear result: whether any disease remains or not, accompanied by a molecular report to help the oncologist make decisions.” The ultimate goal is to move towards more precise and personalised monitoring, enabling earlier detection of recurrence and helping ensure that each patient receives the right treatment at the right time.

Epigenetics opens up new avenues for lung cancer treatment

Small-cell lung cancer (SCLC) represents one of the greatest therapeutic challenges in oncology due to its aggressiveness, rapid growth and high capacity to spread. These characteristics are compounded by the frequent development of resistance to treatment, which makes long-term disease control difficult. Although chemotherapy and immunotherapy have expanded the available treatment options, many patients experience disease progression, highlighting the need to develop more effective therapeutic strategies capable of delivering lasting responses.

Faced with these limitations, epigenetics research is opening up new opportunities to tackle lung cancer through mechanisms that differ from those targeted by conventional therapies. Unlike treatments directed at specific genetic mutations, epigenetic strategies act on mechanisms that regulate gene expression and may play a role in the growth and survival of cancer stem cells. As Jordi Xaus, Chief Scientific Officer (CSO) at Oryzon Genomics, explains, “our goal is to develop new combination strategies that can overcome some of the limitations of current therapies and improve patient prognosis.”

One of Oryzon Genomics' research programmes focuses on the therapeutic potential of iadademstat, a potent and selective inhibitor of LSD1, an epigenetic enzyme involved in regulating genes associated with cell proliferation and differentiation. Inhibiting this enzyme could interfere with mechanisms that promote tumour growth and the persistence of cancer stem cells. Furthermore, preclinical studies suggest that iadademstat could increase the sensitivity of tumour cells to the immune response, opening up new possibilities for combining it with immunotherapy.

Currently, iadademstat is being evaluated in two clinical trials in the United States involving patients with small-cell lung cancer. The first, a Phase I/II trial sponsored by the US National Cancer Institute (NCI), is investigating its combination with immune checkpoint inhibitors in patients with extensive-stage disease. The second, a Phase Ib trial led by Yale University, is evaluating iadademstat in combination with atezolizumab and radiotherapy in patients whose disease persists, progresses or recurs after initial treatment.

Although its clinical efficacy still needs to be confirmed, these studies represent a new avenue of research aimed at expanding therapeutic alternatives for this type of cancer. In Xaus' words, “we hope this research will help expand treatment options and, in the future, improve clinical outcomes for patients with a disease that continues to present significant unmet medical needs.”

The advances highlighted here demonstrate how biotechnology is helping to tackle lung cancer from different perspectives, combining the development of tools to improve patient monitoring with research into new therapeutic alternatives. Although these two areas of research are at different stages of development, they share a common goal: to advance towards increasingly precise and personalised medicine, capable of improving treatment options and addressing patients' needs.